CYP2C19 and metabolic syndrome: However, age, BMI, smoking, alcohol intake, NSTEMI, hypertension, dyslipidemia, concomitant medication, CYP2C19*17 carriers, and metabolizer phenotype were no longer significantly associated with MACE.